The total choline-containing compounds (tCho) spectral profile reflects abnormalities of choline phospholipid metabolism in tumors, as demonstrated with ex vivo studies (1,2). Initially, tCho peak was considered as a dichotomous variable (present or absent) (3). Later, tCho absolute quantification was proposed using either an internal (4) or an external standard of reference (5). Our purpose was to use tCho peak integral as a marker of malignancy in proton magnetic resonance spectroscopy (MRS) of the breast.
Results: Forty-two patients were evaluated for a total of 45 measurements. Eighteen nonmalignant tissues showed no detectable tCho, 8 non-malignant tissues showed an absolute tCho peak integral from 0.99 to 9.03 arbitrary units (au) and 19 malignant lesions showed an absolute tCho peak integral from 1.26 to 19.80 au. An example of the tCho peak is shown in Figure 1 . The diameter of non-malignant tissues was 16.9±7.4 mm; that of malignant lesions was 15.3±6.9 mm (p=n.s.). At ROC analysis (Figure 2 ), the optimal threshold was 1.90 au for absolute tCho peak, with 0.90 (17/19) sensitivity, 0.92 (24/26) specificity, and an area under the curve (AUC) of 0.92 (95% confidence interval 0.82, 1.00) while it was 0.85 au/mL for the normalized tCho peak integral with 0.84 (16/19) sensitivity, 0.89 (23/26) specificity, and an AUC of 0.94 (95% confidence interval 0.88, 1.00) (p = 0.470). A negative correlation (r = 0.571; p = 0.011) was found between the VOI and the normalized tCho peak integral of malignant tissues. The whole examination time was < 40 min, including MR imaging and single-voxel proton MRS.
Conclusion:
In vivo 1.5-T proton MRS of the breast can be added as a last phase after breast MR imaging. Moreover, we showed that breast MRS using tCho peak integral allows to get high values of sensitivity and specificity, with a ROC-AUC higher than 0.90 also for relatively small tissue samples. 
